Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Private Formulations

This article was originally published in The Tan Sheet

Executive Summary

Introduces senior-friendly, easy-open packaging for its 200 mg ibuprofen coated tablets (72 count), extra strength 500 mg acetaminophen caplets and gelcaps (72 count), non-aspirin nighttime pain reliever caplets (80 count), and extra strength enteric-coated 500 mg aspirin tablets (100 count). The company will launch a private-label version of Benadryl complete allergy medicine dye-free liquid caps (diphenhydramine HCl 25 mg) in a 24- count SKU under its Health Cross control label in February 1995. PFI will introduce equivalents to Tylenol flu (20 count) and Tylenol flu nighttime gelcaps (10 count) in December 1994 and February 1995, respectively. Also debuting in February 1995 is PFI's version of Tylenol children's chewable cold tablets in grape flavor, and three private-label products modeled after Alka- Seltzer Plus liquid gels -- cold & cough liquid caps, cold relief liquid caps, and cold relief for nighttime liquid caps

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts